Company & Sponsor Intelligence
Ludwig-Maximilians - University of Munich
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials8
Recruiting3
Completed2
Countries2
Therapeutic footprint
alzheimersdepressionepilepsy
Indexed studies
NCT06224920Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease
alzheimers · COMPLETED
alzheimers · COMPLETED
NCT05172505Transcranial Direct Current Stimulation in a Home Treatment Setting for Major Depression
depression · GermanyNA
depression · GermanyNA
NCT07586150Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
depression · AustriaNA
depression · AustriaNA
NCT06711952German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)
alzheimers · GermanyNA
alzheimers · GermanyNA
NCT05059158Amyloid-β Clearance Mechanisms in Alzheimer's Disease
alzheimers · GermanyRECRUITING
alzheimers · GermanyRECRUITING
NCT00471744HEAD-Study Optimizing the Treatment of Children With BECTS
epilepsy · GermanyPHASE3
epilepsy · GermanyPHASE3
NCT06191952Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults
alzheimers · GermanyNA
alzheimers · GermanyNA
NCT00145132Beta-CIT-SPECT and Neurophysiology in Depression
depression · GermanyPHASE4
depression · GermanyPHASE4
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →